Dr. James J. Salz of the Laser Eye Associates of Los Angeles Contributes to Milestone One Millionth Blade-Free LASIK Procedures
09 Novembro 2006 - 8:07PM
PR Newswire (US)
Dr. Salz Is the First Surgeon in Los Angeles, and One of the First
Nationwide, to Offer Blade-Free LASIK With the IntraLase Method LOS
ANGELES, Nov. 9 /PRNewswire-FirstCall/ -- Dr. James J. Salz of the
Laser Eye Associates of Los Angeles is among a select number of
ophthalmic surgeons whose work has contributed toward the milestone
one millionth all-laser LASIK procedure using the IntraLase
Method(TM), confirming the demand for IntraLase(R) FS laser
technology, according to IntraLase Corp. (NASDAQ:ILSE). Dr. Salz
was the first surgeon in Los Angeles, and one of the first in the
entire country, to offer blade-free LASIK with the IntraLase
Method. The IntraLase FS laser is the first technology for a truly
all-laser, blade-free LASIK procedure, replacing the hand-held
microkeratome blade historically used in creating LASIK corneal
flaps -- the first step of the procedure -- with a computer-guided,
ultra-fast femtosecond (fem-to-second) laser. The IntraLase laser
virtually eliminates the most severe sight- threatening LASIK
complications related to use of the microkeratome and, by creating
an optimal corneal surface below the flap, provides for better
visual outcomes -- taking many patients to 20/20 vision and beyond.
"We have seen a significant improvement in our visual acuity
outcomes and a meaningful reduction in our LASIK complication rate
using the IntraLase Method," said Dr. Salz. "The blade-free
approach is a very comforting message to patients, since it
addresses one of their primary obstacles -- fear of the surgery.
Offering the IntraLase all-laser LASIK platform has been a very
positive experience for our patients, referring doctors and
surgeons." In addition to the Laser Eye Associates of Los Angeles,
the IntraLase FS laser technology has been adopted by such top
ophthalmic teaching institutes as Duke University Medical School,
the Wilmer Eye Institute at Johns Hopkins, the Bascom Palmer Eye
Institute at University of Miami, and Stanford University, all of
which use the technology to train future generations of LASIK
surgeons. Blade-Free Safety and Better Vision with All-Laser LASIK
According to Dr. Salz, the 4th Generation IntraLase FS laser uses
an infrared light beam, generating 60,000 pulses per second, to
prepare the intracorneal bed and create the corneal flap in the
first step of LASIK. * Using an "inside-out" process, the laser
beam is precisely focused to a point within the cornea. * The laser
pulses then create thousands of microscopic bubbles which define
the incision within the intracorneal surface. * Along the edge,
bubbles are then stacked up at a beveled angle -- a feature unique
to the IntraLase Method -- to the corneal surface to complete the
flap. * From start to finish, the IntraLase Method typically takes
15 - 30 seconds. * The physician then exposes the prepared corneal
bed for excimer laser treatment (the second step of LASIK) by
lifting the flap. * The LASIK procedure is complete when the flap
is securely repositioned on its beveled edge. With the IntraLase
laser, the surgeon can precisely control the critical first step of
LASIK. Physician-programmed laser specifications include flap
diameter, depth, hinge location and width, and side-cut
architecture -- factors which can be varied to meet patients'
needs. The IntraLase laser creates a distinctive beveled-edge flap,
which allows for precise repositioning, alignment and seating after
LASIK is completed. This feature reduces the risk of flap
displacement, a complication seen with microkeratome flaps. "The
IntraLase laser makes LASIK safer by replacing the hand-held
microkeratome blade with the computer-guided precision of a laser,"
said Dr. Salz, noting that the completion of approximately one
million IntraLase Method procedures demonstrates an impressive
safety profile for patients. LASIK with the advanced IntraLase
Method, he added, also has been clinically proven to deliver better
visual outcomes in both standard and Custom LASIK procedures with
more patients achieving visual acuity of 20/20, 20/15 and even
20/12.5. About Dr. James Salz Los Angeles LASIK surgeon Dr. James
Salz has more than 22 years experience in corneal refractive
surgery. Dr. Salz has been and still is one of the principal
investigators for the FDA trials involving the use of laser to
correct Nearsightedness (myopia), Farsightedness (hyperopia), and
Astigmatism. Patients who have had problems with previous eye
surgery frequently consult Dr. Salz. He also often is selected by
many other ophthalmologists to perform their eye surgery. About
IntraLase Corp. IntraLase designs, develops, and manufactures an
ultra-fast laser that is revolutionizing refractive and corneal
surgery by creating safe and more precise corneal incisions.
Delivering on the promise of ophthalmic laser technology, the
IntraLase FS laser, related software, and disposable devices
replace the hand-held microkeratome blade used during LASIK
surgery. The unsurpassed accuracy of IntraLase's
computer-controlled femtosecond laser has been shown to improve
safety profiles and visual outcomes when used during LASIK.
Additionally, the IntraLase FS laser creates precision-designed
intracorneal incisions that when combined can be used during
lamellar and penetrating keratoplasty, and intrastromal ring
implantation. IntraLase is presently in the process of
commercializing applications of its technology in the treatment of
corneal diseases that require corneal transplant surgery. The
company's proprietary laser and disposable patient interfaces are
presently marketed throughout the United States and 32 other
countries. IntraLase is headquartered and manufactures its products
in Irvine, California. For additional information, visit the
company's web site: http://www.intralase.com/. DATASOURCE:
IntraLase Corp. CONTACT: Donna Jones of Laser Eye Associates of Los
Angeles, +1-310-360-0609 Web site: http://www.intralase.com/
Copyright
Intralase (NASDAQ:ILSE)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Intralase (NASDAQ:ILSE)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025